Cite
HARVARD Citation
Inokuchi, T. et al. (2019). Long‐term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first‐line biologics. Journal of gastroenterology and hepatology. 34 (8), pp. 1329-1336. [Online].